iRhythm Technologies

iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, which continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days, and Zio AT, which provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iRhythm Technologies posts robust Q4 earnings, eyes global expansion

iRhythm Technologies delivered strong financial results, showcasing growth, innovation, and a positive EBITDA in Q4 2022. The company faces challenges in managing expenses and enhancing integration but has opportunities in new product launches, international expansion, and operational improvements.

iRhythm Technologies posts strong Q1 earnings amidst growth opportunities

iRhythm Technologies delivered robust Q1 2023 results with strong revenue growth and strategic advancements, positioning the company for sustainable expansion.
While challenges like legal inquiries and narrow profitability margins exist, the company's focus on innovation, market penetration, and financial stability bodes well for future prospects.
By capitalizing on strengths like positive clinical data, scalable growth strategies, and market opportunities, iRhythm Technologies aims to navigate challenges and drive long-term success.

iRhythm Technologies posts record revenue growth amidst regulatory challenges

iRhythm Technologies reported strong revenue growth and international expansion milestones despite challenges with FDA warning and product launch delays.
The company's focus on innovation, patient compliance, and market penetration presents opportunities for future growth and advocacy for proactive screening.
While facing challenges in product development and regulatory compliance, iRhythm remains financially robust and strategically positioned for continued success.
Navigating through challenges, iRhythm is poised to capitalize on growth opportunities and strengthen its position in the cardiac monitoring market.

iRhythm Technologies reports strong Q3 growth and eyes global expansion

iRhythm Technologies demonstrated strong financial performance in Q3 2023, with revenue growth, improved patient engagement, and market acceptance of Zio monitoring.
While facing challenges such as gross margin pressure and pricing concerns, iRhythm is focused on strategic growth initiatives and cost management for sustainable profitability.
The company is well-positioned to capitalize on opportunities like silent AFib monitoring, market expansion in Japan, and leveraging guidelines for wider screening to drive future growth.
Overall, iRhythm's Q3 results reflect resilience, strategic planning, and a positive outlook for continued success in 2023 and beyond.

iRhythm Technologies surpasses revenue expectations, eyes international expansion for growth

iRhythm Technologies demonstrated robust financial performance in Q4 2023, exceeding revenue guidance and showcasing growth in key operational metrics.
Despite regulatory challenges and external factors impacting revenue, the company's strategic strengths in product adoption and clinical evidence position it well for future growth.
Opportunities in AI, proactive screening, international expansion, and market disruption present avenues for continued expansion and market leadership.
Balancing challenges with opportunities, iRhythm aims to maintain financial sustainability while driving growth and innovation in the cardiac monitoring space.

iRhythm Technologies reports strong Q1 earnings, eyes global expansion

iRhythm Technologies delivered robust financial performance in Q1 2024, showcasing revenue growth, strategic partnerships, and a focus on sustainable operating leverage improvements.
While facing challenges such as awaiting FDA clearances and managing short-term financial losses, the company remains well-positioned with a strong financial foundation and global growth prospects.
Opportunities lie in upcoming product launches, market expansions, and the exploration of new adjacencies, positioning iRhythm for continued growth and market leadership.
Overall, iRhythm's emphasis on innovation, market expansion, and operational efficiency sets a positive trajectory for future success and shareholder value creation.

iRhythm Technologies excels in Q2 earnings, eyes global expansion

iRhythm Technologies delivered strong financial performance in Q2 2024, driven by product excellence and market expansion efforts.
While facing challenges with compliance and leadership transitions, the company remains focused on growth and operational effectiveness.
Strategic initiatives in primary care, new markets, and product launches position iRhythm well for future success and revenue growth.

iRhythm Technologies reports robust Q3 growth amidst regulatory advancements

iRhythm Technologies showed strong growth and strategic advancements in Q3 2024, focusing on global expansion and product innovation.
While facing financial challenges and regulatory hurdles, the company is actively addressing quality issues and investing in future growth.
Opportunities in international markets, product development, and financial optimization position iRhythm for long-term success and market leadership.
Investors should monitor iRhythm's progress in addressing challenges and capitalizing on growth opportunities for sustainable value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

iRhythm Technologies' (IRTC) CEO Kevin King on Q4 2019 Results - Earnings Call Transcript

IRHYTHM TECH (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: IRHYTHM TECH (IRTC) Q4 Earnings Expected to Decline

IRHYTHM TECH (IRTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IRHYTHM TECH (IRTC) Expected to Beat Earnings Estimates: Should You Buy?

SAN FRANCISCO, Dec.  16, 2019  (GLOBE NEWSWIRE) --  iRhythm Technologies , Inc. (NASDAQ: IRTC) today announced its participation in a new, randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals), sponsored by the Bristol-Myers Squibb-Pfizer Alliance (the Alliance).  The study seeks to determine if earlier detection of atrial fibrillation (AFib) through screening in previously undiagnosed men and women at least 70 years of age in the U.S. ultimately impacts the rate of stroke, compared to usual standard medical care.  The screening arm will utilize iRhythm’s Zio® XT service. 

iRhythm Announces Participation in GUARD-AF Study Focused on Undiagnosed Atrial Fibrillation

SAN FRANCISCO, Nov.  19, 2019  (GLOBE NEWSWIRE) --  iRhythm Technologies , Inc. (NASDAQ: IRTC) announced today that it received a standard notification letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”), dated November 14, 2019, stating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended September 30, 2019, iRhythm is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission (the “SEC”).  This Notice has no immediate effect on the listing of iRhythm's common stock.

iRhythm Technologies Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

iRhythm Technologies' (IRTC) CEO Kevin King on Q3 2019 Results - Earnings Call Transcript

IRHYTHM TECH (IRTC) delivered earnings and revenue surprises of -89.74% and 4.73%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

IRHYTHM TECH (IRTC) Reports Q3 Loss, Tops Revenue Estimates

iRhythm Technologies has been struggling lately, but the selling pressure may be coming to an end soon.

iRhythm Technologies Sees Hammer Chart Pattern: Time to Buy?

Management has expanded selling, general, and administrative expenses in lockstep with gross profit increases. The aggressive strategy has a cost.

Can iRhythm Technologies Have Its Growth and Make a Profit Too?

SAN FRANCISCO, Sept.  05, 2019  (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today the pricing of its underwritten public offering of 1,369,863  shares of its common stock at a public offering price of $73.00  per share, before deducting underwriting discounts and commissions. All of the shares are being offered for sale by iRhythm Technologies. In addition, iRhythm Technologies has granted the underwriters a 30-day option to purchase up to an additional 205,479  shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by iRhythm Technologies, are expected to be $100  million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on September 10, 2019, subject to customary closing conditions. 

iRhythm Technologies Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO, Sept.  04, 2019  (GLOBE NEWSWIRE) --  iRhythm Technologies , Inc. (NASDAQ: IRTC) today announced a collaboration with  Verily , an Alphabet company, focused on the development of solutions aimed at improving the screening, diagnosis and management of patients with atrial fibrillation (AFib). This collaboration brings together iRhythm’s expertise in AI based arrhythmia diagnosis and Verily’s advanced health data analytics technologies to address the millions of patients living with undiagnosed AFib.

iRhythm Announces Collaboration with Verily to Develop Health Management Solutions for Atrial Fibrillation Patients

Alphabet

Verily and iRhythm are teaming up on a new service that aims to help monitor people with a heart rhythm irregularity known as atrial fibrillation.

Alphabet and iRhythm are teaming up on tech to detect irregular heart rhythms

SAN FRANCISCO, Aug.  27, 2019  (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 17th Annual Morgan Stanley Global Healthcare Conference in New York, NY.

iRhythm Technologies to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

iRhythm Technologies' (IRTC) CEO Kevin King on Q2 2019 Results - Earnings Call Transcript

IRHYTHM TECH (IRTC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

iRhythm Technologies' (IRTC) CEO Kevin King on Q1 2019 Results - Earnings Call Transcript

Irhythm Technologies Inc shares traded lower on Wednesday after Kerrisdale Capital said it's short the stock and expects iRhythm’s revenue growth to slow dramatically in coming quarters.

Kerrisdale Short iRhythm Technologies, Claims Company Is Abusing Reimbursement Process

We are short shares of iRhythm Technologies (IRTC), a $2.3bn medical device company trading at over 15x sales despite facing multiple factors that will dramatically cut its revenue growth in the coming years.

News for iRhythm Technologies Stock (IRTC)